Black FridaySave big on focus

Nicotine Pouches vs Cigarettes, by Strength and Risk

R

Roon Team

November 22, 2026·10 min read
Nicotine Pouches vs Cigarettes, by Strength and Risk

Nicotine Pouches vs Cigarettes, by Strength and Risk

The nicotine pouches vs cigarettes comparison comes down to combustion. Pouches expose users to far fewer toxic chemicals than cigarettes because nothing burns, but they deliver similar nicotine. In a 2025 meta-analysis of seven trials, 4 mg pouches delivered about 92% of a cigarette's total nicotine exposure, with a lower, slower peak. FDA authorization does not mean a pouch is safe: it covers 67 nicotine pouch products across three brands, but only 20 ZYN products may claim a lower risk than cigarettes.

  • Combustion is the dividing line. Cigarettes burn tobacco and produce smoke and tar. Pouches deliver nicotine through the mouth with nothing burning.
  • Nicotine dose depends on pouch strength. At 1.5 to 2 mg, total exposure is well below a cigarette's. At 4 mg, roughly equivalent. At 8 mg+, it exceeds a cigarette's.
  • FDA status is narrower than headlines suggest. Of 67 authorized pouches, only 20 ZYN products carry a modified-risk claim. None are "FDA approved."
  • Switching fully is what the studies measured. Short-term biomarker reductions applied to complete switching, not dual use. No long-term outcome data exist.

For the ZYN-specific breakdown, see ZYN vs cigarettes: how much safer.

Nicotine pouches vs cigarettes at a glance

FactorCigarettesNicotine pouches
Burns tobaccoYesNo
Smoke, tar and carbon monoxideYesNone
Nicotine delivered (single use)The reference point in the trialsLower at 1.5 to 2 mg, similar at 3.5 to 4 mg, higher at 8 mg or more
Time to peak nicotine5 to 8 minutes20 to 65 minutes
FDA status"No tobacco product is safe" (FDA)67 products authorized for sale across ZYN, VELO, on!; not "FDA approved"
Modified-risk claim permittedNot applicable20 ZYN products only
Long-term health outcome dataEstablished (CDC: more than 480,000 US deaths a year with secondhand smoke)Not established
AddictiveYesYes (nicotine is addictive regardless of format)

Source: FDA, CDC, Heshmati et al. 2025; checked Nov 14, 2026.

How we compared

Sources: FDA regulatory documents, CDC data, and peer-reviewed pharmacokinetic and biomarker studies. Industry-funded research is labeled as such. We did not use or test any product, and this page is not medical advice. Roon manufactures a zero-nicotine caffeine pouch and links to it at the end; every number below comes from the FDA's published list or the cited study, so you can check it yourself.

Do nicotine pouches give as much nicotine as a cigarette?

At 3.5 to 4 mg, roughly yes in total systemic exposure, but the peak blood level is lower and arrives later. A 2025 systematic review and meta-analysis (Heshmati et al., seven randomized and crossover trials in tobacco-dependent adults) pooled the data by pouch strength against a single smoked cigarette:

Pouch nicotine strengthTotal nicotine exposure vs one cigarettePeak level vs one cigarette
1.5 mg and 2 mgSignificantly lowerSignificantly lower
3.5 mg and 4 mgSimilar (4 mg pooled: 91.73%, 95% CI 85.03 to 98.42%)Lower (3.5 mg significantly lower; 4 mg pooled: 69.15%, 95% CI 58.55 to 79.76%)
8 mg or moreSignificantly higherHigher

Cigarettes peak in 5 to 8 minutes. Pouches, absorbed through the lining of the mouth, peaked at 20 to 65 minutes in these trials, which is why a 4 mg pouch can match a cigarette's total nicotine without matching the spike.

Are nicotine pouches less harmful than smoking?

The FDA's position is that "There is no safe tobacco product," but the chemical profile is very different. Pouches involve no combustion, no smoke and no tar. The FDA's own wording is that "switching completely from cigarettes to FDA-authorized nicotine pouches may reduce exposure to many harmful chemicals found in cigarettes." For scale, the CDC estimates that smoking and secondhand smoke cause more than 480,000 deaths per year in the United States.

Two industry-funded, short-term studies measured what happens when smokers switch:

  • Rensch et al. 2023 (Altria Client Services, maker of on!; PubMed): 144 adult smokers randomized in-clinic for 7 days to on! mint (2, 4 or 8 mg), continued smoking, or no tobacco. 18 of 19 non-nicotine biomarkers of exposure, including the carcinogen marker NNAL, were significantly lower after 7 days than with continued smoking, with reductions of about 42% to 96%, comparable to the group that stopped all tobacco. Nicotine equivalents were not significantly different from smoking, as expected when people still use nicotine.
  • Azzopardi et al. 2022 (British American Tobacco R&D, maker of VELO; PubMed): of 24 to 26 toxicants measured, 22 were not quantifiable in tobacco-free pouches; pouches and NRT had the lowest toxicant profiles, and the authors say further studies are needed to confirm this.

Both are short-term, both are manufacturer-authored, and neither measured disease outcomes. Over a week, removing combustion removed most of the toxicant exposure these studies measured. Whether that translates to fewer cancers or heart attacks over a lifetime remains unproven.

What FDA authorization does and does not mean

The FDA's authorized list (content current Oct 30, 2026) names 67 products across three makers:

Brand (maker on FDA list)Authorized productsModified-risk (lower-risk) claim allowed
ZYN and ZYN ULTRA (Swedish Match USA, Inc.)31 (includes 11 ZYN ULTRA)20 ZYN products only (June 30, 2026)
VELO (Modoral Brands Inc.)24No
on! (Helix Innovations LLC)12No
Total6720

Source: FDA authorized nicotine pouches; checked Nov 14, 2026.

The FDA's language is precise: authorization means a product may be lawfully sold. It "does not mean these products are safe, nor are they 'FDA approved.'"

The 20 ZYN modified-risk orders (June 30, 2026) permit one claim: "Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis." That covers ten ZYN flavors in 3 mg and 6 mg only. No other brand or strength may use it.

Switching, dual use, and quitting

The biomarker reductions in the Rensch trial applied to adults who switched completely. The FDA's framing mirrors this: "switching completely from cigarettes to FDA-authorized nicotine pouches may reduce exposure to many harmful chemicals found in cigarettes," while adding that "fully quitting the use of all forms of tobacco products would most benefit their health."

Dual use (smoking fewer cigarettes while also using pouches) was not what the trials measured, so these studies cannot say whether partial substitution gives the same reductions.

Nicotine pouches are not an FDA-approved cessation product. If you want help quitting tobacco entirely, call 1-800-QUIT-NOW or visit smokefree.gov. Guides on free nicotine patches and nicotine lozenges cover the FDA-approved cessation products.

What the evidence cannot tell you yet

No longitudinal study has followed pouch users long enough to measure cancer incidence, cardiovascular events or mortality. Most toxicant and biomarker data come from manufacturer-authored research. That does not make the findings wrong, but independent replication matters.

Nicotine remains addictive in any format. The FDA's authorized-product page states: "All tobacco products are harmful and potentially addictive. Those who do not use tobacco products shouldn't start." For a broader look at nicotine's effects on the body, that explainer covers the compound itself.

Where the switching evidence applies

  • Adults who currently smoke and switch completely: that is the group the 7-day biomarker data describe.
  • Products on the FDA-authorized list (67 across ZYN, VELO and on!), the only pouches that may lawfully be sold in the US.

Where it does not apply

  • People who do not use tobacco or nicotine now. The FDA's guidance is plain: do not start.
  • People who want to quit nicotine entirely. The CDC notes that counseling and medication treatments can help people quit smoking; 1-800-QUIT-NOW connects you to your state's quitline.

Where each option falls short

Cigarettes lose on toxicant profile. In both studies above, smoking or smoke chemistry carried far more measured toxicants than pouches, and the CDC ties smoking and secondhand smoke to more than 480,000 US deaths a year.

Nicotine pouches lose on long-term evidence. No cancer, cardiovascular or mortality outcome study exists for modern pouches. They still deliver nicotine, which is addictive regardless of format, and the modified-risk claim applies to only 20 of 67 authorized products. Dual use has not been shown to produce the same biomarker reductions as a complete switch.

Who should not use either product

  • Anyone under 21 (federal law prohibits tobacco sales to anyone under 21)
  • Pregnant or breastfeeding individuals
  • People with heart disease or high blood pressure (talk to a clinician)
  • Anyone not currently using tobacco or nicotine ("Those who do not use tobacco products shouldn't start," per the FDA)
  • Keep all nicotine products away from children and pets

Talk to your prescriber before using any nicotine product if you take medication or have a health condition.

Related from Roon

Frequently Asked Questions

Do nicotine pouches have tar?

No. Tar is a byproduct of burning tobacco. Because nicotine pouches contain no tobacco leaf and involve no combustion, they produce zero tar. The Azzopardi et al. 2022 analysis found that 22 of 24 to 26 toxicants measured were not quantifiable in tobacco-free pouches.

Is a 6 mg pouch stronger than a cigarette?

The Heshmati et al. 2025 meta-analysis did not pool a 6 mg tier separately. At 4 mg, total exposure was about 92% of a cigarette's; at 8 mg+, significantly higher. A 6 mg pouch may fall between those brackets, but the review gives no pooled estimate for that strength.

Are VELO and on! FDA authorized too?

Yes. The authorized list includes 24 VELO products (Modoral Brands Inc.) and 12 on! products (Helix Innovations LLC), alongside 31 ZYN products. Neither VELO nor on! carries a modified-risk claim. Only the 20 ZYN products (3 and 6 mg) may state they pose a lower risk than cigarettes.

Do nicotine pouches cause cancer like cigarettes?

No long-term cancer data exist for modern pouches. Cigarettes cause cancer largely through toxicants released by combustion, and pouches eliminate combustion. The Rensch 2023 trial showed NNAL (a carcinogen-exposure marker) dropped significantly after 7 days of switching. But biomarker reduction is not cancer prevention, and the follow-up was only one week.

Is the nicotine in pouches less addictive than in cigarettes?

Same molecule, different speed. Cigarettes peak in 5 to 8 minutes; pouches in 20 to 65 minutes. A slower peak does not remove the addiction risk: the FDA says all tobacco products are "potentially addictive," and the Heshmati authors raise concern about dependence among recreational users.

The Pouch Habit, Minus the Nicotine

If you have decided nicotine is something you want to leave behind, but you still like the ritual of a pouch, Roon keeps the format with zero nicotine and zero tobacco.

What goes under the lip instead is caffeine: 80 mg per pouch, alongside 60 mg L-theanine, 25 mg methylliberine (Dynamine) and 5 mg theacrine (TeaCrine). Methylliberine extends the window: a randomized crossover PK study (n=12) found that co-dosing it with caffeine stretched caffeine's half-life from 7.2 to 15 hours with no higher peak (study). That trial used 100 mg methylliberine and 150 mg caffeine, about 4x and 1.9x what a single Roon pouch contains, so the mechanism applies directionally but those exact figures do not. Felt duration is 6 to 8 hours; cap is 4 pouches a day, none within 8 hours of bedtime.

Roon is from $9.16 per tin on a 12-tin subscription. It is not a cessation product and will not treat nicotine withdrawal. For more on caffeine pouches as a nicotine-free option, that guide covers the category. For quitting support, the resources above are where to start.

Sources

  • FDA, "Nicotine Pouch Products Authorized by the FDA," content current as of 10/30/2026. fda.gov
  • FDA CTP Newsroom, "FDA Authorizes 20 ZYN Nicotine Pouches to Be Marketed with Specific Modified Risk Claim," June 30, 2026. fda.gov
  • CDC, "About Commercial Tobacco." cdc.gov
  • Heshmati J et al., "Nicotine pouch pharmacokinetics compared to smoked tobacco: A systematic review and meta-analysis." Drug Alcohol Depend Rep 2025;17:100389. PubMed
  • Rensch J et al., "A Randomized, Controlled Study to Assess Changes in Biomarkers of Exposures Among Adults Who Smoke That Switch to Oral Nicotine Pouch Products Relative to Continuing Smoking or Stopping All Tobacco Use." J Clin Pharmacol 2023;63(10):1108-1118. Industry-funded (Altria Client Services). PubMed
  • Azzopardi D, Liu C, Murphy J, "Chemical characterization of tobacco-free 'modern' oral nicotine pouches and their position on the toxicant and risk continuums." Drug Chem Toxicol 2022;45(5):2246-2254. Industry-funded (British American Tobacco R&D). PubMed
  • FDA, "Premarket Tobacco Product Marketing Granted Orders." fda.gov
  • Smokefree.gov, "Speak to an Expert." smokefree.gov

Written by Roon Team

Share

The Roon Journal

Sharper days, in your inbox.

Subscribe for exclusive discounts, early drops, and quiet notes on focus, sleep, and cognitive performance, straight from the Roon team.

  • Early access
  • Save up to 54%
  • New posts & tips

The Roon Community

Follow along on Instagram and TikTok.